Anti-CD19 CAR Composition for Persistent, Lower-Toxicity B-Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR therapies for B-cell malignancies suffer from significant side effects such as cytokine release syndrome, B cell aplasia, and neurotoxicity, while also lacking persistence and efficacy, necessitating the development of antigen-targeted CARs with reduced toxicities and improved stability.
Innovation Solution
Design of a chimeric antigen receptor (CAR) comprising a promoter, leader sequence, single chain variable fragment (scFv), hinge region, transmembrane domain, co-stimulatory signaling domain, and intracellular signaling domain, specifically targeting CD19-positive B cells, with optional EF-1α or MND promoter sequences, to enhance therapeutic efficacy and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR therapies are used to treat B-cell malignancies, then remission rates are improved, but severe side effects such as cytokine release syndrome, B cell aplasia, and neurotoxicity occur
Solution Approach 1:
The patent modifies the CAR construct parameters by selecting specific co-stimulatory domains (CD28, 4-1BB, or OX40) and intracellular signaling domains (CD3ζ) to change the functional characteristics of CAR-T cells. This parameter optimization aims to achieve effective tumor killing while reducing toxic side effects through careful domain selection and configuration.
Solution Approach 2:
The CAR construct is designed as a composite structure integrating multiple functional domains: extracellular antigen-binding domain (anti-CD19 scFv), hinge region, transmembrane domain, and intracellular signaling domains. This composite architecture combines the advantages of different domains to achieve both efficacy and safety.
2Reliability
If existing CART therapies are administered, then complete remission is achieved in some patients, but the therapies lack persistence and require repeated administrations
Solution Approach 1:
The patent employs dynamic co-stimulatory domains (CD28, 4-1BB, OX40) that can adaptively regulate CAR-T cell behavior. These domains enable the CAR-T cells to dynamically respond to tumor microenvironment signals, enhancing their persistence and long-term survival capabilities while maintaining anti-tumor activity.
Solution Approach 2:
The designed CAR construct with optimized signaling domains aims to enable continuous anti-tumor activity of CAR-T cells through sustained persistence in the body. The co-stimulatory domains provide continuous activation signals that maintain T cell functionality and prevent exhaustion, ensuring prolonged therapeutic action.
3Reliability
If personalized CART cell therapy is performed, then improved remission and survival rates are observed, but the manufacturing complexity and cost increase significantly
Solution Approach 1:
The CAR construct is segmented into modular functional domains (extracellular domain, hinge region, transmembrane domain, intracellular signaling domain) that can be independently optimized and assembled. This modular segmentation simplifies the design and manufacturing process while maintaining therapeutic efficacy.
Solution Approach 2:
The patent designs a universal CAR construct framework with standardized signaling domains (CD3ζ combined with co-stimulatory domains) that can be applied to treat various CD19-positive B-cell malignancies. This universal design reduces manufacturing complexity by using a common platform across different patient treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designed CAR effectively targets CD19-expressing malignant B cells, improving remission rates and survival in B-cell malignancies with reduced toxicity and enhanced stability, addressing the limitations of current therapies.
Implementation Method 1
an antigen specific targeting region comprises a hu CD-19 specific single chain Fragment variable (scFv) fragment, that binds to the CD19 expressing malignant B cells
Data Source
AI summary
The present invention provides to develop novel chimeric antigen receptor (CAR) encoded by an open reading frame 3 (ORF3) mRNA and amino acid sequences of any one of SEQ ID NO: 1 to SEQ ID NO: 109 specific to CD19 against hematologic malignancies associated with expression of Cluster of Differentiation 19 (CD19). The invention relates to the design of a synthetic CAR mRNA sequence comprising hu anti CD19 scFv, a hinge, a Transmembrane domain, a co-stimulatory domain and a CD3ζ signaling domain, where with the costimulatory is CD27 or 41BB for targeting and destroying malignant B-cells. This disclosure features anti-CD19 CAR T-cell therapy for antigen binding domains, directed to B cell malignancies, described herein.